AstraZeneca eyes rapid expansion of China trials

AstraZeneca has struck a deal with Peking University that will swiftly expand the number of early-stage clinical trials underway in China. AstraZeneca is looking for a much greater involvement in China, both to sell new medicines to the rapidly growing market as well as develop new contacts in the medical and scientific community. Its new Clinical Pharmacology Unit will make investments in new facilities with an eye to training more people and advancing therapies in infections, diabetes, and cardiovascular diseases. Despite a series of controversies over corruption in China's regulatory work, the country continues to attract a tremendous amount of interest from drug developers.

- see this release from AstraZeneca
- read the report on China from MarketWatch

Related Articles:
China now leads India in ongoing clinical trials. Report
China's pharma market steams ahead. Report
China pushes drug development as R&D soars. Report
Bridge Pharma sees growth in China drug studies. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.